Research Collaborations

OMG was founded by Drs. Brett Cordes (L) and Craig Woods (R), serial entrepreneurs with expertise in technology transfer, regulations, and human and veterinary clinical research.  OMG serves as a centralized resource for advancing translational research into a clinical environment and acquire clinically relevant data in real-world patients.

Drs. Cordes and Woods have decades of industry experience with a track record of developing biomedical products with dual applications in human and veterinary medicine including:

• antivenoms and antitoxins
• biological scaffolds and cell based therapeutics
• drug delivery devices and tumor imaging agents
• immuno-therapeutics

CLINICAL Studies: OMG can design and implement comparative clinical studies to advance:

• therapeutics and biologics;
• medical devices and diagnostics; and
• other biomedical innovations.

Our veterinary clinical studies are performed similar to human subjects research, with owner consenting and use of standardized case report forms.  As veterinarians, our first priority is patient safety and all clinical research projects undergo an assessment of the potential risks and benefits to our patients.

BIO-specimens: Comparative clinical biospecimens are highly valuable for multi-omics research, discovering biomarkers and for the development of diagnostics.   OMG can collect clinical veterinary biospecimens in patients with naturally occurring comparative diseases, and we have an ongoing biobanking program (visit our Biorepository Page)

Under our co-development program, OMG can invest our own resources to clinically evaluate, develop and commercialize technologies for veterinary medicine.  In return, our co-development partners get access to comparative data to support their human development efforts, and a percentage of revenue generated from veterinary commercialization.

OMG will consider a range of technologies for co-development, but we have particular interests in:

• Diagnostics for infectious, autoimmune, immune mediated, or other diseases that are comparative and translatable between humans and canines;
• Bioscaffolds to accelerate tissue repair or deliver biological substances; and
• Medical devices including monitoring and imaging devices, surgical instruments, and medical implants.

Less than 5% of academic assets are successfully commercialized, and many continue to incur patent maintenance fees with eroding patent protection.  Many academic assets are supported by laboratory data, and therefore perceived as developmentally immature and high-risk.  Without more convincing data, many innovations are destined to become stranded assets.

OMG team members have history of working with ASU and UA technology transfer offices to reduce biomedical innovations to practice in veterinary patients, and can work with universities and the private sector companies to:

• assess technology portfolios;
• determine which technologies have applications for animal health;
• establish regulatory, development and licensing strategies; and
• conduct clinical studies to increase value, obtain real-world evidence, and facilitate out-licensing for human and veterinary medicine.